The 1st European conference brought together key actors on HCV, including drug user community representatives, harm reduction experts, health care professionals, pharmaceutical companies, researchers and policy makers to develop pathways for effective health responses and to open treatment for those who need it.

One of the highlights during the conference was the presentation of the 'Berlin Declaration', a pressing call to national and European policy makers, to ensure better access and quality of hepatitis treatment for the most marginalised groups and individuals.